Leverage the speed and scalability of FastPharming to rapidly produce COVID-19 biologics.
Combat COVID-19 with FastPharmingProduction of a range of recombinant products including monoclonal antibodies, antigens for subunit vaccine design, lysosomal enzymes, and many more
Explore FastPharmingFull range of development and manufacturing services required to move projects from pre-clinical, market launch, to ongoing commercial requirements phases
Learn More About iBio's ServicesPlant-based expression shortens development timelines and provides for seamless scale-up. Glycan engineering in plants affords greater control and can deliver increased product potency and quality.
Explore FastPharmingThe past few years have seen an explosion in interest in immuno-oncology approaches that leverage monoclonal antibodies (mAbs) as therapeutics for a range of cancers. These therapies take ...
Biologics company iBio, is focused on developing therapeutics and vaccines using a novel plant-based system. It recently announced a worldwide licensing agreement with Planet Biotech to develop ...
Accelerated development of vaccines is essential to public health and pandemic preparedness, both for the current COVID-19 pandemic and future threats. iBio is developing multiple vaccine ...
iBio, Inc. is developing a decoy molecule as a therapeutic against SARS-CoV-2. Recently licensed from Planet Biotechnology, the candidate is a recombinant protein made from human angiotensin ...
The COVID-19 pandemic sweeping across the globe is pushing innovation to the cutting edge throughout the biopharma industry. More rapid development of novel diagnostics, therapeutics, and ...
At the start of April 2020, the global number of confirmed COVID-19 cases was rapidly approaching 1.5 million; the death toll: over 80,000. And these numbers will likely have changed ...
Immeasurable efforts are underway to develop treatments and vaccines to address the COVID-19 pandemic. Numerous discovery methods and technologies are currently being explored in clinical trials ...
N-Glycosylation is a critical component of many protein-based therapeutics, required for appropriate stability, immunogenicity, and pharmacokinetics. In addition, it is essential for key ...
iBio (NYSE American:IBIO) is continuing its transition from a licensing business to a manufacturing services provider and developer of proprietary biologics. Central to the initiative is a new ...
There is a chronic shortage of organs available for transplant. Bioprinted organs could dramatically increase accessibility to all patients in need of transplants. Some simpler biofabricated ...
Post-translational modification is a critical step in the synthesis of biotherapeutic molecules. Among these alterations to the original naked protein, glycosylation may be the most significant ...
iBio has expanded its CDMO service offerings to include independent sterile liquid cGMP fill-finish services to support the preclinical and clinical trial needs of drug developers. This new ...
iBio offers development and manufacturing services for biologic drug substances and drug products, built around our proprietary plant-based platform technology. Client support is offered from ...
Mammalian cell culture is widely used for biologic drug substance production, but the high cost and long development times pose challenges to the implementation of this technology in many parts ...
Imagine you work at a virtual biopharma with a highly specialized biopharmaceutical ready for advanced development. You contact the one CDMO that you’ve been told undoubtedly has the most ...
The current trade conflict between the world's biggest economies — the United States and China — has resulted in both countries imposing billions of dollars’ worth of tariffs on each other’s ...
Recently, contract manufacturers have taken the conventional definition of outsourcing, and set it on fire. Traditionally, CMOs provided capacity reservoirs for pharma companies to tap as ...
Outsourcing to Contract Development and Manufacturing Organizations (CDMOs) has been on the rise, driven by increasingly complex drug candidates and the expertise they require, and now, ...
Monoclonal antibodies (mAbs) represent the fastest growing class of therapeutics [1,2] and have been especially beneficial in the treatment of cancer [3]. Since the approval of the first ...
According to the agreement, Delaware, US-based iBio will provide process development and manufacturing services at its Texas facility, and will assist CC-Pharming in preparing a site for ...
Introduction Classical Swine Fever (CSF) is a highly contagious hemorrhagic disease affecting pigs. CSF outbreaks have caused substantial economic damages to the swine industry worldwide, ...
Introduction Therapeutic glycoproteins represent a predominant disease treatment category among biopharmaceuticals approved or in clinical development. N-linked glycosylation is a very important ...
AzarGen Biotechnologies (Pty) Ltd (Stellenbosch, South Africa), announced that it has received grant status for the patent application: PRODUCTION OF HUMAN PULMONARY SURFACTANT PROTEIN-B IN ...
AzarGen Biotechnologies (Pty) Ltd (Stellenbosch, South Africa) announced that it has received grant status for the patent application: SYNTHETIC PROMOTER CONSTRUCT FOR TRANSGENE EXPRESSION ...
AzarGen Biotechnologies, South Africa’s only private plant-based biopharmaceutical company, is imagining a world-class commercial plant-made pharmaceutical facility for South Africa.
You probably won’t find a lot of presidents of successful contract manufacturing organizations gleefully operating the forklift inside the manufacturing plant, but Barry Holtz is no ordinary ...
Introduction Since the commercialization of the first therapeutic monoclonal antibody (mAb) in 1986, this class of biopharmaceutical products has grown exponentially. As of November 2014, ...
Introduction In recent years, the plant‐made pharmaceutical (PMP) community has made significant progress in bringing therapeutics to the clinic: Elelyso™ (Pastores et al., 2014; ...
BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the ...
FastPharming overcomes issues presented by mammalian expression systems:
FastPharming optimizes gene-expression, glycosylation, and purification parameters to deliver a robust process for your APIs.
The FastPharming system transfects at large-scale to easily and reliably deliver biologics in clinical trial or commercial quantities.
In-line labelling allows serialization of vials and bottles for greater quality assurance of mAbs, viral vectors, and other biologics.
An experienced analytical staff provides method development and validation support with expertise in protein characterization using mass spectrometry.
When the time is right, iBio facilitates insourcing by designing and building your own environmentally sustainable FastPharming facilities.
The FastPharming platform produces a variety of recombinant products including:
iBio offers the CDMO capabilities needed to develop and deliver biologics to market - process development, scale-up, cGMP manufacturing, bioanalytical product characterization, aseptic fill/finish, and quality and regulatory support.